Jim Van Meerten's  Instablog

Synta Pharmaceuticals (SNTA) was added to the Barchart Van Meerten Speculative portfolio.  They are a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. Synta has a unique chemical compound library, an integrated discovery engine, and a diverse pipeline of clinical- and preclinical-stage drug candidates with distinct mechanisms of action and novel chemical structures. All Synta drug candidates were invented by Synta scientists using our compound library and drug discovery capabilities. Synta has a partnership with GlaxoSmithKline for the joint development and commercialization of its lead investigational drug candidate, elesclomol, which is in a global, pivotal Phase 3 clinical trial for the treatment of metastatic melanoma.

• 96% Barchart technical buy signal
• 16 new highs in the last month
• Up 61.28% in the last month
• Relative Strength Index 85.23%

Disclosure: Jim Van Meerten through Marketocracy Capital Management has an interest in the stocks mentioned in this blog.  

Disclosure: I am long SNTA.